AstraZeneca has also joined Oxford University in developing a vaccine candidate, and if proven effective, authorization could also be signed off in February or March. Great Britain has already approved it.
“If there are three [perhaps four] vaccines available, supply and reach will increase. However, I expect that would be a ramp up period, and we will continue the graduated path we’re on now,” Capofari said, adding that most Americans should expect to be inoculated in the late summer.
While Warp Speed’s missed goal could be discouraging to Americans, Schaffner stressed, “Don’t make too much of this, there are lots of simple explanations about why there’s been this deficit. But the biggest one is, they overpromised.”
Rachel Bucchino is a reporter at the National Interest. Her work has appeared in The Washington Post, U.S. News & World Report and The Hill.